Federated Hermes’s Cardiff Oncology CRDF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.25K Buy
4,811
+2,558
+114% +$4.06K ﹤0.01% 1889
2026
Q1
$3.65K Buy
+2,253
New +$4.63K ﹤0.01% 1921
2022
Q3
Sell
-196
Closed -$1K 2157
2022
Q2
$1K Buy
196
+44
+29% +$74 ﹤0.01% 2033
2022
Q1
$1K Buy
+152
New +$538 ﹤0.01% 2074

Other funds holding CRDF

Federated Hermes's CRDF Position: Q2 2026 in Review

Federated Hermes increased its Cardiff Oncology (CRDF) stake by 114% in Q2 2026, buying an estimated $4.06K and bringing the position to 4,811 shares worth $6.25K. The position accounts for ﹤0.01% of the portfolio, ranked #1889.

Federated Hermes first reported a position in CRDF in Q1 2022 and has held it in 4 quarters since. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Federated Hermes held 4,811 shares of Cardiff Oncology worth $6.25K as of Q2 2026.
  • Federated Hermes bought 2,558 Cardiff Oncology shares in Q2 2026, an estimated $4.06K.
  • Cardiff Oncology made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1889 holding.
  • Federated Hermes first reported a position in Cardiff Oncology in Q1 2022 and has held it in 4 quarters since.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.